Skip to main content Skip to search Skip to main navigation

EC: New Entries in the MDCG Borderline Manual

The Medical Device Coordination Group (MDCG) has updated its manual on the classification of products that are on the borderlines between medtech and other regulatory categories (Version 4).

The following newly added cases illustrate current regulatory decisions on qualification and classification:

  • Red blood cell additive solutions containing adenine
    Medical Device, Class III
    Adenine exerts metabolic/pharmacological effects on RBCs; therefore, the solution is classified as part of a Class III device.
  • Dual-action cream with menthol and capsaicin
    Not a medical device
    Principal mode of action is pharmacological (via receptor activity); classified as a medicinal product.
  • Lactose vaginal tablets
    Not a medical device
    Mode of action is metabolic, based on lactic acid bacteria metabolizing lactose into lactic acid.
  • Microabrasion dental stain removers (tooth whitening)
    Not a medical device
    Purely cosmetic purpose (aesthetic improvement), no proven medical benefit.
  • Medical examination table covers
    Medical device
    Intended to prevent disease transmission (infection prevention), thus meeting the definition of a medical device.
  • Mobile sterile air system
    Not a medical device
    Controls the environment (air purification/laminar flow), without direct action in or on the human body.

The updates highlight the strict distinction between medical purpose and cosmetic, pharmacological, or purely environmental functions. Manufacturers must provide robust scientific evidence of the principal mode of action to ensure correct regulatory qualification.


Source:

EC: Manual on borderline and classification for medical devices under Regulation (EU) 2017/745 on medical devices and Regulation (EU) 2017/746 on in vitro diagnostic medical devices


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
Previous
Next